Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report

BACKGROUND: Pembrolizumab has significantly improved outcomes in patients with advanced non-small cell lung cancer. Combining programmed death-1 inhibitor with stereotactic body radiotherapy showed a slight toxicity and good benefits in recent clinical trials. However, patients infected with human i...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dongqi, He, Chuanchun, Xia, Yaoxiong, Du, Yaxi, Zhang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911965/
https://www.ncbi.nlm.nih.gov/pubmed/29681240
http://dx.doi.org/10.1186/s13256-018-1667-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911965/
https://www.ncbi.nlm.nih.gov/pubmed/29681240
http://dx.doi.org/10.1186/s13256-018-1667-2

Ejemplares similares